Osteopontin as a Serologic Marker for Metastatic Uveal Melanoma: Results of a Pilot Study

Reiniger, I. W.; Wolf, Armin; Welge–Lüßen, Ulrich; Mueller, A. J.; Schaller, U. C.

doi:10.1016/j.ajo.2006.11.040

Cited by 29 publications

(28 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other serum markers have been analyzed in the context of metastasis detection in UM patients by different groups [22][23][24][25]. A significant increase in the serum levels of the melanoma inhibitory activity protein (MIA) was detected in UM patients who developed metastases.…”

Section: Discussionmentioning

confidence: 99%

GDF-15: a novel serum marker for metastases in uveal melanoma patients

Suesskind

Schatz

Schnichels

et al. 2011

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

GDF-15: a novel serum marker for metastases in uveal melanoma patients

Suesskind

Schatz

Schnichels

et al. 2011

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Elevated plasma levels have been observed in patients with advanced or metastatic cancers, including cutaneous melanoma [12, 13]. Increased OPN plasma levels have recently also been described in patients with metastatic uveal melanoma [9, 10, 17]. …”

Section: Discussionmentioning

confidence: 99%

“…The study followed the principles expressed in the Declaration of Helsinki and had been approved by the local ethics committee. Data of these 32 patients were already partly used in previous studies [10]. …”

Section: Methodsmentioning

confidence: 99%

“…Two promising proteins have recently been reported, namely ‘melanoma inhibitory activity’ (MIA) [6,7,8] and osteopontin (OPN) [9, 10]. The latter is expressed by various cell types and its expression has been shown to enhance tumorigenicity and metastases [11], to lead to more aggressive tumor growth in various cancers [12] and to increase the invasive behavior of cutaneous melanoma cells [13].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Osteopontin and ‘Melanoma Inhibitory Activity’: Comparison of Two Serological Tumor Markers in Metastatic Uveal Melanoma Patients

Haritoglou¹,

Wolf²,

Maier

et al. 2009

Ophthalmologica

Self Cite

View full text Add to dashboard Cite

Background: Evaluation of the protein osteopontin (OPN) as a potential new marker in comparison to melanoma inhibitory activity (MIA) for screening and detection of metastatic uveal melanoma. Methods: Plasma levels of 32 patients with uveal melanoma were analyzed for OPN and MIA by enzyme-linked immunosorbent assay (ELISA). Fourteen of these patients had clinically detectable liver metastases. Results: Median plasma concentration of OPN in patients with metastatic disease was 152.01 ng/ml compared to 47.39 ng/ml in patients without clinically detectable metastases (p < 0.001). The difference between the median MIA plasma levels in patients with (13.11 ng/ml) and patients without (5.64 ng/ml) metastatic disease was also statistically significant (p < 0.001). No correlation could be found between MIA or OPN levels and tumor height in patients without clinically detectable metastases. Conclusion: The proteins MIA and OPN seem to be promising tumor markers for the metastasis screening in patients with uveal melanoma.

show abstract

“…OPN signaling enhances malignancy by giving cells a survival/growth advantage and by augmenting attributes that confer increased aggressiveness by activating the expression of genes and functions that contribute to metastasis [23,24,25,26,27,28,29]. Multiple studies have demonstrated that OPN is associated with tumor progression and metastasis; in particular, reports have shown increased levels of OPN in melanoma-derived cell lines [29,30,31,32,33,34,35,36]. …”

Section: Introductionmentioning

confidence: 99%

Elevated Osteopontin Levels in Metastatic Melanoma Correlate with Epigenetic Silencing of Breast Cancer Metastasis Suppressor 1

et al. 2010

View full text Add to dashboard Cite

Objective: Breast cancer metastasis suppressor 1 (BRMS1) has been shown to functionally reduce the metastatic potential of melanoma. We also previously reported that BRMS1 negatively regulates the expression of the oncoprotein osteopontin (OPN). This study was carried out to assess the clinical relevance of BRMS1 and OPN in melanoma. Methods: Epigenetic regulation of BRMS1 was assessed by treating clinically derived melanoma cell lines with the demethylating agent 5-aza-2′-deoxycytidine (DAC) and the histone deacetylase inhibitor trichostatin A (TSA), followed by sodium bisulfite modification and methylation-specific PCR. Assessments of BRMS1 and OPN levels were performed using immunoblotting, quantitative real-time RT-PCR or reporter assays. RNA silencing was employed to abrogate the expression of OPN in melanoma-derived cell lines. The in vivo relevance of our findings was determined with experiments using athymic nude mice. Results: The reduced expression of BRMS1 in surgically excised melanoma specimens correlated with increased OPN expression during the progression from primary to metastatic melanoma. Treatment with DAC and TSA elevated BRMS1 levels, but caused an inconsistent change in OPN gene expression. Abrogating the expression of OPN in BRMS1-deficient metastatic melanoma-derived cell lines retarded the growth of melanoma tumor xenografts in athymic nude mice. Conclusion: While treatment with DAC and TSA may not be a universally applicable treatment alternative in melanoma, silencing the expression of OPN in metastatic melanomas that have lost expression of BRMS1 is a potential option for therapeutic intervention.

show abstract

Osteopontin as a Serologic Marker for Metastatic Uveal Melanoma: Results of a Pilot Study

Cited by 29 publications

References 6 publications

GDF-15: a novel serum marker for metastases in uveal melanoma patients

GDF-15: a novel serum marker for metastases in uveal melanoma patients

Osteopontin and ‘Melanoma Inhibitory Activity’: Comparison of Two Serological Tumor Markers in Metastatic Uveal Melanoma Patients

Elevated Osteopontin Levels in Metastatic Melanoma Correlate with Epigenetic Silencing of Breast Cancer Metastasis Suppressor 1

Contact Info

Product

Resources

About